


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+26.64%
+5.29%
-16.76%
+16.46%
-13.51%
AZN
Astrazeneca
$205.55
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Expands stock buyback program
AZN Price Performance
$89.94 (+128.54%)
$88.99 (+130.98%)
$75.97 (+170.57%)
$77.25 (+166.08%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Revenue increase YoY

Earnings decline YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Expands stock buyback program
Future
Future

Earnings are forecast to grow
![]()
AZN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
AZN Street Sentiment is extremely bullish and have positive views on the near-term outlook
AZN has Low risk level
Risks Indicators

Investors losing confidence

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Feb 03, 2026
Upgrade
Hold
Jan 29, 2026
Initiate
Buy
Citigroup
Dec 06, 2025
Reiterate
Overweight
JP Morgan
Nov 12, 2025
Reiterate
Buy
Jefferies
Nov 12, 2025
Reiterate
Overweight
JP Morgan
PFE
Pfizer
27.58
+0.42%
MRK
Merck Company
121.41
+1.78%
HCM
HUTCHMED (China) Limited
14.76
+0.07%
TEVA
Teva Pharma
33.98
+0.18%
NVS
Novartis AG
163.10
+1.16%
What is AZN current stock price?
What are AZN stock strengths?
What is AZN Risk Level?
What is AZN market cap and volume?
What is AZN current Stock IQ?
Should I buy AZN stock right now?
Is AZN a Strong Buy right now?
What does a 'Strong Buy' rating mean for AZN?
What does a 'Strong Sell' rating mean for AZN?
What factors influence AZN's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+26.64%
+5.29%
-16.76%
+16.46%
-13.51%
AZN
Astrazeneca
Current Price
$205.55
Runners Also Watch
PFE
Pfizer
27.58
+0.42%
MRK
Merck Company
121.41
+1.78%
HCM
HUTCHMED (China) Limited
14.76
+0.07%
TEVA
Teva Pharma
33.98
+0.18%
NVS
Novartis AG
163.10
+1.16%

AZN Price Performance
$89.94 (+128.54%)
$88.99 (+130.98%)
$75.97 (+170.57%)
$77.25 (+166.08%)
AZN Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Revenue increase YoY

Earnings decline YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Expands stock buyback program
Future
Future

Earnings are forecast to grow
![]()
AZN Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
AZN Street Sentiment is extremely bullish and have positive views on the near-term outlook
AZN has Low risk level
Risks Indicators

Investors losing confidence

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Feb 03, 2026
Upgrade
Hold
Jan 29, 2026
Initiate
Buy
Citigroup
Dec 06, 2025
Reiterate
Overweight
JP Morgan
Nov 12, 2025
Reiterate
Buy
Jefferies
Nov 12, 2025
Reiterate
Overweight
JP Morgan
AZN Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Expands stock buyback program
AZN Latest Analysis
China charges former AstraZeneca executive – what it means for global pharmaceutical firms. AstraZenecas former China head has been formally charged with medical insurance fraud illegal trading and unlawful collection of personal information more than a year after he first came under investigation – casting a shadow over the Swedish-British drug makers expansion in its second-largest
Fri Feb 13, 2026
Big Deal Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca. After months of rumors drove up its share price the Chinese drug company has unveiled a record licensing deal with AstraZeneca only to see its stock tumble
Thu Feb 12, 2026
Heres How Much $100 Invested In AstraZeneca 5 Years Ago Would Be Worth Today. AstraZeneca (NYSE:) has outperformed the market over the past 5 years by 2.92% on an annualized basis producing an average annual return of 14.97%. Currently AstraZeneca has a market capitalization of $317.33 billion.
Wed Feb 11, 2026
Astras Ex-Chief in China Formally Charged With Insurance Fraud. AstraZeneca Plcs former China head Leon Wang has been formally charged with medical insurance fraud unlawful collection of personal information and illegal trade with the case heading to court.
Wed Feb 11, 2026
AstraZeneca awards $3.4 million to United States nonprofits to expand healthcare access.
Wed Feb 11, 2026
AstraZeneca sets sights on 25 blockbusters by 2030 to fuel $80B revenue ambition. After ending 2025 with a strong fourth quarter AstraZeneca management has doubled down on its ambitious $80 billion by 2030 revenue target outlining a roadmap to have more than 25 blockbuster medicines by the end of the decade.During AZs Q4 earnings call CEO Pascal Soriot highlighted an
Wed Feb 11, 2026
AstraZeneca PLC declares $2.17 dividend.
Tue Feb 10, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.